Bluejay Diagnostics, Inc. (BJDX): Entry into a Material Definitive Agreement
Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029339001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 2, 2026, between Bluejay Diagnostics, Inc., a Delaware corporation (the “ Company ”), and e
How this was made
The 30-second read
Why it matters
A material definitive agreement for a securities purchase typically precedes closing of a financing; the market often reprices for dilution and potential warrant overhang once the final terms are known.
Market read
This is a primary-source disclosure of a new financing agreement (common stock and warrants) that can create dilution/overhang risk for BJDX until deal economics are confirmed.
What to watch
Traders should focus on the agreement’s missing economic details (subscription amount, share/warrant pricing, conversion/anti-dilution, escrow mechanics, and closing conditions) to gauge dilution and probability of closing.
Background
The company’s 8-K references a Securities Purchase Agreement dated June 2, 2026 and an unregistered sales of equity securities disclosure (Reg D / Section 4(a)(2)).
Ticker impact
Bluejay Diagnostics filed an 8-K disclosing entry into a material definitive securities purchase agreement for an unregistered equity/warrant issuance.
Near-term bias modestly negative to neutral (dilution/overhang risk), with direction depending on the final pricing/size disclosed in the agreement.
The article is a primary SEC 8-K entry into a securities purchase agreement; however, the excerpt does not include the key economic terms (share price, total proceeds, warrant coverage), limiting precision on magnitude.
Market effects
Microcap biotech/diagnostics issuances can increase perceived financing risk across similar small-cap names, especially when warrant coverage is meaningful.
No clear regional linkage beyond US small-cap risk appetite.
Limited; this is company-specific US capital markets activity.
Counterpoint
If the financing terms are priced at a premium with limited warrant coverage, the overhang could be smaller than typical dilutive deals.
Key entities
- issuerBluejay Diagnostics, Inc.
Subject of the 8-K and party to the securities purchase agreement for an unregistered equity/warrant issuance.
- escrow_agentContinental Stock Transfer & Trust Company
Escrow agent named for deposit of subscription amounts under the transaction documents.
- company_counselHogan Lovells US LLP
Named as company counsel in the agreement exhibit.
